Estonia In Vitro Diagnostics (IVD) Market: By Technology (Molecular Diagnostics (Hepatitis C, Hepatitis B, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr Virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV), Covid- 19)), Tissue Diagnostics (H&E Stains, Special Stains, Advanced Stains, Digital Scanners), Sequencing (Clinical, NIPT, and Research Use Only), Country

Estonia In Vitro Diagnostics (IVD) Market size was valued at USD x billion in 2023 and is poised to grow at a CAGR of x% from 2024-2030. The Estonia in-vitro diagnostics (IVD) market is a dynamic and rapidly evolving sector within the healthcare industry. IVD refers to medical devices and diagnostic techniques that are used to analyze samples derived from the human body, such as blood, urine, and tissue, outside the body. These tests provide crucial information for the early detection, diagnosis, and management of diseases and conditions. Molecular diagnostics in IVD market are growing at fastest rate due to increasing prevalence of various diseases such as Hepatitis B and C, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV) and Covid- 19. Hospital Acquired Infections (HAI) represent a major clinical, epidemiologic, and economic problem because they are linked to high morbidity and mortality rates and hospitalization costs. In 2022, hospital-acquired infections accounted for highest market value of 690.4 thousand Euros in molecular diagnostics and are expected to reach 704.9 thousand Euros by 2029.

Tissue diagnostics testing continues to serve as one of the gold standards for cancer diagnosis. The type of cancer, the stage, and the extent to which the disease has infiltrated healthy tissue may all be diagnosed via a biopsy. In 2021, Tissue Diagnostics accounted for a market the value of 1.2 Mn Euro and is expected to reach 2.2 Mn Euro by 2029. Estonia is 17 years into its long-term genome sequencing program. The samples are stored in a repository, the Estonian Genome Centre, based in the University of Tartu. As a part of its National Personalized Medicine program in Estonia, from 2018 they carried out a project to recruit and genotype 100,000 new biobank participants. In Estonia, majority of NIPT samples are analyzed on Illumina device.